Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on July 29, 2021. The report discloses a specific event under Item 8.01 (Other Events) regarding a new grant received by the Company.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is a grant award of $155,964.
Material Changes
The Company received a grant from the National Institutes of Health (NIH) to fund a patient preference information study. This study involves participants in the Company's Early Feasibility Clinical Trial for its Orion Visual Cortical Prosthesis. The entire grant amount will be paid to UCLA as a subcontractor to conduct the research.
Outlook and Management Commentary
Management indicates that this study is intended to help the Company better understand the benefits of the Orion Visual Cortical Prosthesis and the decision-making process of potential patients regarding implantation. No specific financial guidance or risk factors beyond the scope of the clinical study were detailed in this specific report.
Investor Verification Checklist
- Verify the status of the Early Feasibility Clinical Trial for the Orion Visual Cortical Prosthesis.
- Confirm the terms of the subcontract agreement with UCLA regarding the $155,964 NIH grant.
- Review subsequent filings for updates on the patient preference study results.
- Check the Company's latest 10-K or 10-Q for comprehensive financial health data not included in this 8-K.